Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.

被引：0
|
作者：
Mascarenhas, John
Maher, Keri Renee
Rampal, Raajit
Bose, Prithviraj
Podoltsev, Nikolai Alexandrovich
Hong, Junshik
Wang, Xulong
Kye, Steve
Harrison, Claire
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] VCU Massey Comprehens Canc Ctr, Richmond, VA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[5] Yale Sch Med, New Haven, CT USA
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[7] Karyopharm Therapeut, Newton, MA USA
[8] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6594
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naive myelofibrosis and moderate thrombocytopenia.
    Scandura, Joseph
    Gerds, Aaron Thomas
    Ritchie, Ellen K.
    Wang, Xulong
    Kye, Steve
    Rampal, Raajit
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)
    Maher, Keri
    Rampal, Raajit K.
    Bose, Prithviraj
    Podoltsev, Nikolai A.
    Harrison, Claire N.
    Hong, Junshik
    Wang, Xulong
    Chamoun, Kamal
    Mascarenhas, John
    BLOOD, 2023, 142
  • [3] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naive Myelofibrosis.
    Yacoub, Abdulraheem
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    CANCER RESEARCH, 2021, 81 (13)
  • [4] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
    Winton, Elliott F.
    Devos, Timothy
    Oh, Stephen T.
    Platzbecker, Uwe
    Wadleigh, Martha
    Jun, Susie
    Lee, Peter
    Deng, Wei
    Gupta, Vikas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Scandura, Joseph M.
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Li, Qing
    Boxhammer, Rainer
    Brown, Barbara
    Jegg, Anna-Maria
    Harrison, Claire N.
    Mascarenhas, John
    NATURE MEDICINE, 2025,
  • [7] Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
    Mead, Adam
    Mascarenhas, John
    Gerds, Aaron
    Luptakova, Katarina
    Christo, Jessica
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    Harrison, Claire
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 101 - 102
  • [8] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
    Yacoub, Abdulraheem
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 115 - 116
  • [9] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
    Yacoub, Abdulraheem
    Erickson-Viitanen, Susan
    Zhou, Feng
    Assad, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
    Mascarenhas, John
    Harrison, Claire
    Luptakova, Katarina
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
12345